|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 139.56 USD | -1.16% |
|
+2.57% | -1.60% |
| Capitalization | 14.08B 11.83B 10.8B 10.29B 19.09B 1,277B 19.87B 125B 49.73B 614B 52.8B 51.71B 2,198B | P/E ratio 2025 * |
28.4x | P/E ratio 2026 * | 20.2x |
|---|---|---|---|---|---|
| Enterprise value | 12.49B 10.5B 9.58B 9.13B 16.94B 1,133B 17.64B 111B 44.13B 545B 46.85B 45.89B 1,950B | EV / Sales 2025 * |
4.39x | EV / Sales 2026 * | 3.44x |
| Free-Float |
98.7% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Neurocrine Biosciences, Inc.
| 1 day | -1.16% | ||
| 1 week | +2.57% | ||
| Current month | +2.57% | ||
| 1 month | +2.94% | ||
| 3 months | -8.41% | ||
| 6 months | +11.64% | ||
| Current year | -1.60% |
| 1 week | 136.46 |  | 142.14 |
| 1 month | 129.17 | | 142.14 |
| Current year | 129.17 | | 142.16 |
| 1 year | 84.23 | | 160.18 |
| 3 years | 84.23 | | 160.18 |
| 5 years | 71.88 | | 160.18 |
| 10 years | 31.55 | | 160.18 |
| Manager | Title | Age | Since |
|---|---|---|---|
Kyle Gano
CEO | Chief Executive Officer | 53 | 10/10/2024 |
| Director of Finance/CFO | 47 | 31/10/2017 | |
Sanjay Keswani
CTO | Chief Tech/Sci/R&D Officer | 56 | 01/06/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kevin Gorman
BRD | Director/Board Member | 68 | 31/12/2007 |
Richard Pops
BRD | Director/Board Member | 64 | 31/03/1998 |
| Chairman | 78 | 30/04/2011 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -3.96% | 13.65% | 253 M€ | |
| 0.00% | 3.81% | 1 M€ | |
| -.--% | 1.85% | 4 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.16% | +2.57% | +13.82% | +33.56% | 14.08B | |
| -1.28% | +0.73% | +18.94% | +206.60% | 947B | |
| -0.56% | +5.01% | +55.85% | +45.86% | 578B | |
| -0.08% | +0.11% | +17.14% | +54.39% | 395B | |
| -0.73% | +0.88% | +22.42% | +23.38% | 367B | |
| -3.51% | +6.69% | +34.80% | +10.32% | 303B | |
| -1.53% | +2.12% | +19.72% | +29.17% | 298B | |
| +0.20% | +4.87% | +24.14% | +49.65% | 295B | |
| +5.25% | -15.84% | -50.55% | -35.93% | 208B | |
| -2.21% | +9.93% | +28.03% | +56.46% | 207B | |
| Average | +0.17% | +2.46% | +18.43% | +47.35% | 361.13B | |
| Weighted average by Cap. | +0.19% | +2.76% | +23.33% | +78.49% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 2.84B 2.39B 2.18B 2.08B 3.86B 258B 4.01B 25.35B 10.05B 124B 10.67B 10.45B 444B | 3.41B 2.86B 2.61B 2.49B 4.62B 309B 4.81B 30.36B 12.03B 148B 12.77B 12.51B 532B |
| Net income | 502M 421M 385M 367M 680M 45.5B 708M 4.47B 1.77B 21.86B 1.88B 1.84B 78.3B | 708M 594M 543M 517M 959M 64.18B 999M 6.31B 2.5B 30.84B 2.65B 2.6B 110B |
| Net Debt | -1.58B -1.33B -1.22B -1.16B -2.15B -144B -2.24B -14.12B -5.6B -69.06B -5.94B -5.82B -247B | -2.35B -1.97B -1.8B -1.72B -3.18B -213B -3.31B -20.93B -8.29B -102B -8.81B -8.62B -367B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/02/26 | 139.56 $ | -1.16% | 869,278 |
| 06/02/26 | 141.20 $ | +2.37% | 1,154,003 |
| 05/02/26 | 137.93 $ | +0.05% | 1,272,936 |
| 04/02/26 | 137.86 $ | -0.81% | 935,665 |
| 03/02/26 | 138.98 $ | +0.98% | 996,884 |
Delayed Quote Nasdaq, February 09, 2026 at 09:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NBIX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition